JP2013517782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517782A5 JP2013517782A5 JP2012550441A JP2012550441A JP2013517782A5 JP 2013517782 A5 JP2013517782 A5 JP 2013517782A5 JP 2012550441 A JP2012550441 A JP 2012550441A JP 2012550441 A JP2012550441 A JP 2012550441A JP 2013517782 A5 JP2013517782 A5 JP 2013517782A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fvii
- seq
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 229920001184 polypeptide Polymers 0.000 claims 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims 25
- 102100023804 Coagulation factor VII Human genes 0.000 claims 7
- 108010023321 Factor VII Proteins 0.000 claims 7
- 229940012413 factor vii Drugs 0.000 claims 7
- 108010054265 Factor VIIa Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 229940012414 factor viia Drugs 0.000 claims 5
- 102100022641 Coagulation factor IX Human genes 0.000 claims 3
- 208000032843 Hemorrhage Diseases 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 230000000740 bleeding effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 108010076282 Factor IX Proteins 0.000 claims 2
- 108010014173 Factor X Proteins 0.000 claims 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960004222 factor ix Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102400000069 Activation peptide Human genes 0.000 claims 1
- 101800001401 Activation peptide Proteins 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010073391 Platelet dysfunction Diseases 0.000 claims 1
- 208000027276 Von Willebrand disease Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000007386 factor VII deficiency Diseases 0.000 claims 1
- 201000007219 factor XI deficiency Diseases 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10151940 | 2010-01-28 | ||
| EP10151940.3 | 2010-01-28 | ||
| US30272310P | 2010-02-09 | 2010-02-09 | |
| US61/302,723 | 2010-02-09 | ||
| PCT/EP2011/051139 WO2011092242A1 (en) | 2010-01-28 | 2011-01-27 | Factor vii fusion polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013517782A JP2013517782A (ja) | 2013-05-20 |
| JP2013517782A5 true JP2013517782A5 (enExample) | 2014-02-27 |
Family
ID=42272531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550441A Withdrawn JP2013517782A (ja) | 2010-01-28 | 2011-01-27 | 因子ｖｉｉ融合ポリペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120321607A1 (enExample) |
| EP (1) | EP2528943A1 (enExample) |
| JP (1) | JP2013517782A (enExample) |
| CN (1) | CN102753575A (enExample) |
| WO (1) | WO2011092242A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104661685A (zh) | 2012-10-15 | 2015-05-27 | 诺和诺德保健Ag（股份有限公司） | 因子vii缀合物 |
| BR112016008039A2 (pt) | 2013-10-15 | 2017-10-17 | Novo Nordisk Healthcare Ag | polipeptídeos do fator vii da coagulação |
| JP6566536B2 (ja) * | 2014-06-16 | 2019-08-28 | 国立大学法人山口大学 | フォワードプライマー |
| CN118516337B (zh) * | 2024-07-22 | 2024-09-20 | 深圳市卫光生物制品股份有限公司 | 一种凝血因子vii截短体及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE60225118T2 (de) * | 2001-02-05 | 2009-03-05 | Novo Nordisk Health Care Ag | Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden |
| AU2002249096B2 (en) | 2001-03-22 | 2007-06-28 | Novo Nordisk Health Care Ag | Coagulation factor VII derivatives |
| US7052868B2 (en) | 2001-09-27 | 2006-05-30 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| US6960657B2 (en) | 2001-11-02 | 2005-11-01 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| ES2293088T3 (es) | 2002-09-25 | 2008-03-16 | Novo Nordisk Health Care Ag | Polipeptidos del factor vii de la coagulacion humana. |
| MX2007001294A (es) * | 2004-08-17 | 2008-03-04 | Zlb Behring Gmbh | Polipeptidos modificados que dependen de vitamina k. |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| US20110040073A1 (en) * | 2006-04-07 | 2011-02-17 | Novo Nordisk Healthcare A/G | Covalent Factor VII-Tissue Factor Complex |
| EP1867660A1 (en) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
-
2011
- 2011-01-27 CN CN2011800075445A patent/CN102753575A/zh not_active Withdrawn
- 2011-01-27 EP EP11702418A patent/EP2528943A1/en not_active Withdrawn
- 2011-01-27 US US13/574,896 patent/US20120321607A1/en not_active Abandoned
- 2011-01-27 WO PCT/EP2011/051139 patent/WO2011092242A1/en not_active Ceased
- 2011-01-27 JP JP2012550441A patent/JP2013517782A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537087A5 (enExample) | ||
| JP2012082206A5 (enExample) | ||
| JP2012532601A5 (enExample) | ||
| KR102172937B1 (ko) | 장기-작용성 응고 인자 및 그의 제조 방법 | |
| JP2012530504A5 (enExample) | ||
| KR20180029262A (ko) | 인자 ix 융합 단백질 및 이의 제조 방법 및 사용 방법 | |
| JP2014530253A5 (enExample) | ||
| JP2017160222A5 (enExample) | ||
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| RU2015142981A (ru) | Белки rsv в предшествующей слиянию конформации и их применение | |
| HRP20161353T1 (hr) | Rekombinantni rsv antigeni | |
| JP2017018125A5 (enExample) | ||
| JP2012530761A5 (enExample) | ||
| JP2014113157A5 (enExample) | ||
| JP2011525363A5 (enExample) | ||
| JP2011502479A5 (enExample) | ||
| NZ596778A (en) | Glucose-regulating polypeptides and methods of making and using same | |
| RU2003110419A (ru) | Варианты человеческого фактора свертывания крови vii | |
| WO2016004906A2 (zh) | 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用 | |
| RU2015118580A (ru) | НОВЫЙ ВЫСОКО ФУНКЦИОНАЛЬНЫЙ ФЕРМЕНТ, ИМЕЮЩИЙ МОДИФИЦИРОВАННУЮ СУБСТРАТНУЮ СПЕЦИФИЧНОСТЬ β-ГЕКСОЗАМИНИДАЗЫ ЧЕЛОВЕКА И ПРОЯВЛЯЮЩИЙ УСТОЙЧИВОСТЬ К ПРОТЕАЗЕ | |
| JP2015504052A5 (enExample) | ||
| JP2015164424A5 (enExample) | ||
| JP2017521074A5 (enExample) | ||
| RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
| JP2018537089A5 (enExample) |